Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. by Ikeda Maho et al.
Ikeda et al., Page 1 
Simvastatin attenuates Trinitrobenzene sulfonic acid-induced colitis, but not 
Oxazalone-induced colitis 
 
Maho Ikeda, Fuminao Takeshima*, Hajime Isomoto, Saburo Shikuwa, Yohei Mizuta, 
Yoshiyuki Ozono, Shigeru Kohno 
 
Second Department of Internal Medicine and *Department of General Medicine, Nagasaki 
University School of Medicine, Nagasaki,  
 
Running title: Simvastatin protects against TNBS colitis 
 
Key words: Simvastatin, statin, TNBS, colitis 
 
Corresponding author: 
Fuminao Takeshima, MD, PhD. 
Department of General Medicine, 
1-7-1 Sakamoto  






Ikeda et al., Page 2 
Abstract: 
Purpose: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene 
sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. 
Results: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease 
in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic 
protocol, no significant difference in body weight reduction was observed between 
simvastatin-treated and control mice. IFN-γ release from LP cells was significantly 
suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast 
to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either 
weight reduction or inflammatory grade in OXA colitis.  
Conclusion: Our results indicate that simvastatin  negatively regulates inflammation in 
TNBS-induced colitis but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin 
suppressed the Th1-polarized immune response.  Our findings suggest that simvastatin has 
potential effects as a therapeutic agent in human inflammatory bowel disease, particularly 
Crohn’s disease.
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Introduction:  
Statins are known to be 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, and are widely used to reduce cholesterol in patients with 
hyperlipidemia leading to cardiovascular morbidity (1). Recent clinical studies have 
suggested that statins may also have immunosuppressive effects and be useful in the 
treatment of inflammatory diseases. For example, clinical trials have demonstrated that 
simvastatin and pravastatin have an effect on the prevention of transplant rejection after heart 
transplantation (2, 3). Statins also reduced high sensitive C-reactive protein levels (4, 5) and 
vascular proinflammatory cytokines, such as TNF-α, IL-1 and IL-6 (6) in hyperlipidemia 
patients. 
Although the molecular mechanisms of such anti-inflammatory activities remain 
unclear, recent studies have provided some insight. Certain statins are able to inhibit the 
interaction between LFA-1 and ICAM-1 (7). Moreover, statins also prevented IFN inducible 
MHC class 2 expression in non-professional APC (8). In vivo, using murine models, Youssef 
et al. (9) demonstrated that atorvastatin rescued experimental Th1 encephalomyelitis, 
inhibiting the Th1-mediated immunoresponse. Leung et al. (10) also reported an 
anti-inflammatory role for simvastatin in experimental Th1 arthritis. Recently, it was reported 
that simvastatin reduced the expected number and volume of new gadolinium-enhancing 
lesions in relapsing-remitting multiple sclerosis patients in a small open label trial (11). 
Atorvastatin has also been reported to decrease the disease score and vascular risk factors in 
patients with rheumatoid arthritis in a double-blind placebo controlled trial (12). 
Based on these results, statins appear to be beneficial for other Th1-mediated 
autoimmune diseases. Human inflammatory bowel disease (IBD), such as Crohn’s disease 
(CD) and ulcerative colitis (UC), are believed to be autoimmune conditions resulting from an 
abnormal mucosal T cell response to bacteria in the lumen. In CD, mucosal T cells exhibit 
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Th1 phenotype, whereas ulcerative colitis is believed to have Th2 phenotype, but this has not 
been clearly demonstrated. Three recent articles have shown that pravastatin (13), 
rosuvastatin  (14) and simvastatin (15) are able to reduce disease activity and colonic 
inflammation in dextran-sulfate (DSS)-induced colitis in mice.  
Trinitrobenzene sulfonic acid (TNBS)-induced colitis is a colitis model that results 
in transmural infiltration and an IL-12-driven, Th1-mediated response (16, 17). In contrast, 
oxazalone (OXA)-induced colitis is caused by a polarized Th2-mediated response (16). We 
can thus utilize both TNBS-induced and OXA-induced murine experimental colitis as models 
of human IBD in order to test whether statins are able to suppress such colitis. The present 
study was conducted in order to elucidate whether statins can inhibit the inflammation of 
TNBS-induced or OXA-induced colitis 
Methods:  
Animals   All experiments were performed in accordance with the Guidelines for Animal 
Experimentation of Nagasaki University. Six- to eight-week-old SJL/J male mice were 
obtained from SLC Inc (Shizuoka, Japan). 
Experimental colitis models   Colitis was induced in SJL/J mice as described previously 
(18, 19). Briefly, in order to presensitize mice, abdominal skin was shaved and 150 l of 
either TNBS (2.5% in 50% ethanol) or OXA (3% in 100% ethanol) was applied. Five days 
after presensitization, mice were intrarectally administered 150 l of a solution of 1.5% 
TNBS or 1% OXA dissolved in 0.9% NaCl and mixed with an equal volume of ethanol. 
Control mice (CO) were given ethanol in place of TNBS. 
Treatment protocols   For the prophylactic protocol, mice were administered 10 mg/kg or 
40 mg/kg i.p. simvastatin daily from 5 days before to 7 days after rectal administration of 
TNBS or OXA. For the therapeutic protocol, mice were administered 10 mg/kg or 40 mg/kg 
i.p. simvastatin daily for a total 7 days after rectal administration of TNBS or OXA. Control 
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mice (NS) for simvastatin treatment received 0.9% NaCl in place of simvastatin. 
Histological grading of colitis   Sections of the proximal, middle, and distal colon were 
fixed in 3% buffered formalin. Tissue sections were subjected to hematoxylin and eosin 
staining using standard techniques for histological examination. Degree of inflammation was 
graded semiquantitatively, as described previously (17). The grading system was as follows: 
0 = no inflammation; 1 = very low-level inflammation; 2 = low-level inflammation; 3 = 
high-level inflammation with high vascular density and thickening of the colon wall; and 4 = 
transmural infiltration with loss of goblet cells, high vascular density and thickening of the 
colon wall. Grading was performed in blinded fashion. 
Isolation of lamina propria (LP) cells   Colons were washed with PBS and were digested 
with dispase (2 mg/ml, Gibco BRL, Grand Island, NY) at 37°C for 1 hour in complete media 
(RPMI 1640 media supplemented with 4% FCS, 2 mM L-glutamine, 10 mM HEPES, 100 
U/ml penicillin, 100 g/ml streptomycin and 250 ng/ml amphotericin) in order to remove the 
epithelial compartment, including intraepithelial lymphocytes. Samples were then minced 
into small pieces and further digested with collagenase (1 mg/ml, Gibco BRL) and dispase (2 
mg/ml) for another hour at 37°C. After washing, cells were purified using the 40%/70% 
Percoll gradient method to remove epithelial and dead cells. Cells at the interface were 
isolated and washed with PBS. 
Analysis of cytokine production   Colonic LP cells were cultured at 2 × 105 cells in 150 l 
of media (DMEM/F-12 Media containing 1% FCS, 100 U/ml penicillin, 100 g/ml 
streptomycin, 250 ng/ml amphotericin, 2 mM L-glutamine, 0.05 mM 2ME, 10 mM HEPES, 
1 mM sodium butyrate and 1x SITE-3). Cells were either unstimulated or stimulated with 
anti-TCR-β. Supernatant was collected after five days of culture, spun down for cell removal, 
and frozen at -80°C until cytokine analysis. OptEIATM cytokine sandwich ELISA kits from 
PharMingen were used to assess the expression of IL-4, IL-5, IFN- and TNF-, in 
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accordance with the manufacturer’s instructions.   
Statistical analysis   All data are expressed as means ± SEM. Differences between groups 
were examined for statistical significance using Student’s t-test. A P value of less than 0.05 
denoted the presence of a statistically significant difference. 
 
Results 
Simvastatin prevents mice from developing TNBS colitis   In order to determine whether 
simvastatin suppresses immune-mediated pathology in vivo, we investigated the effects of 
simvastatin in TNBS-induced colitis (prophylactic protocol). As shown in Figure 1, SJL/J 
mice treated with TNBS alone (NS) manifested a severe illness characterized by weight loss 
and diarrhea peaking on day 4 after intrarectal administration of TNBS. A significant 
decrease in body weight (15.1 ± 1.4%; n=20) was seen in TNBS-treated mice in comparison 
with the CO group (ethanol-treated mice). Simvastatin dose-dependently suppressed the 
decrease in body weight in TNBS-treated mice. Administration of high-dose (40 mg/day) 
simvastatin, but not low-dose (10 mg/day) simvastatin, reduced the decrease in body weight 
(6.6 ± 2.0%, n=19 vs. 16.4 ± 1.8%, n=6, respectively; p< 0.01, high-dose simvastatin in 
comparison with NS). On macroscopic examination (Figure 2), while NS colons showed 
severe colitis involving the entire colon and shortening of colon length, colons from 
high-dose simvastatin-treated TNBS mice were similar in appearance to those from CO mice. 
In addition, as shown in Figure 3a, on microscopic examination, NS colons revealed 
transmural inflammation involving all layers of the bowel wall with numerous granulocytes, 
monocytes and lymphocytes. Conversely, the colons from high-dose simvastatin-treated 
TNBS mice were almost free of colitis. Inflammatory grade was also markedly improved in 
high-dose simvastatin-treated TNBS mice in comparison with NS mice (1.4 ± 0.3, n=14 vs. 
2.9 ± 0.2, n=17; p<0.001) (Figure 3b). 
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We then investigated the effects of simvastatin after onset of TNBS-induced colitis 
(therapeutic protocol). No significant differences in body weight reduction were observed 
between simvastatin-treated (therapeutic protocol) and NS mice (Figure 4; 12.9 ± 2.3%, n=11 
vs. 12.8 ± 2.0%, n=13). With regard to inflammatory grade, the mean score in 
simvastatin-treated (therapeutic protocol) TNBS mice was significantly lower than that in NS 
mice significantly (Figure 5; 2.3 ± 0.2, n=11 vs. 3.0 ± 0.2, n=13; p<0.05). 
Simvastatin suppresses Th1 cytokine production in TNBS colitis   The cytokine profile of 
T lymphocytes in TNBS-induced colitis was investigated by stimulating colonic LP cells 
from NS mice via the antigen receptor (anti-TCR-β) and analyzing cytokine expression in the 
supernatants. As expected, colonic LP cells from NS mice produced large amounts of Th1 
cytokines (IFN-γ and TNF-α) upon antigen-receptor stimulation (Figure 6). In contrast, very 
little production of IL-4 or IL-5 was detected. Next, we investigated whether simvastatin 
(prophylactic protocol) suppresses the Th1-polarized immune response induced by TNBS. 
IFN-γ release upon antigen-receptor stimulation was significantly suppressed in mice 
receiving high-dose simvastatin (simvastatin, 115.9 ± 36.6 pg/ml, n=8 vs. NS, 436.8 ± 51.2 
pg/ml, n=7; p<0.001). TNF-α release upon antigen-receptor stimulation was lower in mice 
receiving high-dose simvastatin than in NS mice, but this difference was not significant 
(193.2 ± 29.6 pg/ml, n=8 vs. 312.9 ± 60.8 pg/ml, n=7; p=0.11). 
Simvastatin did not prevent mice from developing OXA colitis   In order to determine 
whether simvastatin suppresses another immune-mediated colitis model, we investigated the 
effects of simvastatin on the development of OXA-induced colitis, which is caused by a 
polarized Th2-mediated response. In contrast to TNBS colitis, even high-dose simvastatin 
(prophylactic protocol) had no suppressive effects on either weight reduction (Figure 7a; 
simvastatin, 13.3 ± 1.5%, n=19 vs. NS, 15.5 ± 1.1%, n=20; p=0.27) or inflammatory grade 
(Figure 7b; 2.8 ± 0.2%, n=19 vs. 3.2 ± 0.2, n=20; p=0.39).  
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Discussion:  
 In the present study, we provide experimental evidence that simvastatin negatively 
regulates the inflammatory response in TNBS-induced colitis. Moreover, we demonstrated 
that prophylactic administration is more effective than therapeutic administration in treating 
TNBS-induced colitis. TNBS-induced colitis is hapten-induced model of human IBD. 
Intestinal inflammation in this model does not result from the direct effects of this chemical, 
but rather from delayed hypersensitivity to TNBS-modified self-antigens. The highly 
prophylactic effects of simvastatin on the development of TNBS-induced colitis suggest that 
statins may suppress not only acute inflammation, but also immune-mediated pathology.  
 Recently, special attention has paid to the effect of statins on rodent colitis models. 
Sasaki et al. (13) reported that pravastatin relieved DSS-induced acute colitis in mice and 
promoted colonic endothelial nitric-oxide synthase (eNOS) mRNA expression. That study 
also demonstrated that the protective effects of pravastatin were not present in 
eNOS-deficient mice. Similarly, Naito et al. (14) demonstrated that rosuvastatin suppresses 
intestinal inflammation and inhibits the increase in TNF-α, and the decrease in eNOS in 
DSS-induced acute colitis in mice. Lee et al. (15) showed that simvastatin inhibited 
TNF-α-induced IL-8 gene expression and nuclear transcription factor κB (NF-κB) 
transcriptional activity in intestinal epithelial cells. That study also showed that simvastatin 
prevents DSS-induced acute colitis in mice. Suzuki et al. (20) reported that fluvastatin 
inhibits colonic inflammation and incidence of colorectal dysplasia in DSS-induce chronic 
colitis in mice. Jahovic et al. (21) demonstrated that simvastatin and fluvastatin reduces 
colonic inflammation and serum TNF-α levels in TNBS-induced colitis in rats. These results, 
taken together with those of the present study, suggest that statins are potential therapeutic 
agents for human IBD. 
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 Several studies (22, 23) have demonstrated that statins can promote protective Th2 
development and inhibit Th1 development in rodent models of Th1-mediated autoimmune 
disease. Liu et al. (22) demonstrated that atorvastatin ameliorates experimental autoimmune 
myocarditis, which is related to Th1 responses, accompanied by reductions in IFN-γ and IL-2 
and the promotion of IL-4 and IL-10 production. Similarly, Aprahamian et al. (23) 
demonstrated that simvastatin reduces serum TNF- and IFN-γ levels and increases IL-4 and 
IL-10 transcript levels in lymph nodes in a murine lupus model. In vitro, Arora et al. (24) 
demonstrated that simvastatin-treated murine dendritic cells promote T cells to secret IL-4, 
IL-5 and IL-13, and this cytokine secretion profile was correlated with increased expression 
GATA-3 and decreased expression of T-bet by T cells. 
Although CD and UC share clinical and pathological characteristics, each has a 
distinct cytokine production profile. CD is a Th1-mediated inflammatory disease (25, 26). 
Various studies have shown predominant synthesis of IL-12 by macrophages and IFN-γ by T 
cells. In addition, mucosal lymphocytes in CD express high levels of active STAT-4, which is 
activated by IL-12 receptor signals and is necessary for the induction of Th1-associated genes. 
In this study, we used TNBS-induced colitis as a model of CD, and demonstrated that 
simvastatin suppresses the Th1-polarized immune response induced by TNBS, similarly to 
other Th1-mediated autoimmune animal models. 
On the other hand, based on various reports, such as the association between UC and 
the production of autoantibodies as well as the increased secretion of the Th2-related 
immunoglobulin subclasses IL-5 and IL-13, UC is believed to be a Th2-mediated 
inflammatory disease (25). In this study, we used OXA-induced colitis as a model of UC but 
simvastatin did not show any suppressive effects on either weight reduction or inflammatory 
grade in this model. In support of these results, there is a single case report of UC after 
pravastatin treatment (27). The authors speculated that statins may reveal previously 
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quiescent UC in susceptible individuals. There are several reports on other Th2-mediated 
autoimmune diseases. Mckay et al. (28) demonstrated that simvastatin reduces IL-4 and IL-5 
production in bronchoalveolar lavage fluid in a murine model of allergic asthma. In contrast, 
a randomized double blind crossover trial (29) did not find any anti-inflammatory effects of 
simvastatin in patients with asthma. Based on the results regarding the effects of statins in 
promoting Th2-bias (22-24), as well as the present data, the use of statins in Th2-mediated 
autoimmune disease must be evaluated cautiously. Further basic and clinical studies  Further 
basic and clinical studies assessing the effects of statins on Th2-mediated autoimmune 
disease are thus necessary. 
 In conclusion, we demonstrated that simvastatin negatively regulates inflammation in 
TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin 
suppressed a Th1-polarized immune response. Our findings suggest that simvastatin has 
potential effects as a therapeutic agent in human IBD, particularly CD. 
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Prophylactic administration of simvastatin improves the body weight reduction induced 
by TNBS. A significant decrease in body weight in TNBS-treated mice (NS) was 
observed. *p<0.001 vs. controls (CO; ethanol-treated mice) Administration (prophylactic 
protocol) of high-dose (high), but not low-dose (low), simvastatin reduced this decrease 
in body weight. **p<0.01 vs. NS 
 
Figure 2 
Prophylactic administration of simvastatin improves the macroscopic lesions induced 
by TNBS. CO: ethanol-treated mice. NS: TNBS-treated mouse, showing marked edema 
and shortening of colon length. high: high-dose simvastatin. Note the marked reduction 
in colitis.  
 
Figure 3 
Prophylactic administration of simvastatin improves the histologic lesions induced by 
TNBS. (a) Microscopic appearance of colon (H&E stain; magnification ×200). CO: 
ethanol-treated mice. NS: TNBS-treated mice, showing severe transmural colitis. high: 
high-dose of simvastatin (prophylactic protocol). Note the marked reduction in colitis. 
(b) Inflammatory grade. Simvastatin dose-dependently improves the inflammation 




Therapeutic administration of simvastatin shows no effect on body weight reduction. 
CO; ethanol-treated mice. NS; TNBS-treated mice. High: administration (therapeutic 
protocol) of high-dose simvastatin. 
 
Figure 5 
Therapeutic administration of simvastatin improves histologic lesions induced by TNBS. 
CO; ethanol-treated mice. NS; TNBS-treated mice. High; administration (therapeutic 




Prophylactic administration of simvastatin suppresses Th1 cytokine production induced 
by TNBS. Colonic lamina propria cells were isolated and stimulated with anti-TCR-β 
and concentrations of INF-, TNF-, IL-4 and IL-5 were measured in supernatants. 
IFN- release was significantly suppressed in mice receiving high-dose simvastatin. 
*p<0.001 vs. NS. 
 
Figure 7 
Simvastatin shows no effect on body weight reduction (a) and histologic legions (b) 
induced by OXA. CO; ethanol-treated mice. NS; OXA-treated mice. High; 
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